SPCR are currently enrolling participants onto a new study for Alzheimer’s Disease called GAIN.

 

 

Cortexyme Gain Trial Video from Gain Trial on Vimeo.

 

Alzheimer’s disease is the most common cause of dementia, accounting for approximately 70% of all cases. People with Alzheimer’s disease gradually lose their ability to remember events, recall names and words, control their emotions, recognise people and look after themselves. Currently, there are no effective treatments available to prevent or slow down the progression of Alzheimer’s disease.

 

GAIN (GingipAIN Inhibitor for Treatment of Alzheimer’s Disease) is a new clinical trial that is investigating the effectiveness of a new drug on the memory and recall ability of people with Alzheimer’s disease.

 

 

The GAIN study is based on a growing body of scientific evidence suggesting the bacteria P.gingivails – commonly associated with gum disease – may cause Alzheimer’s disease. Periodontitis is a common but serious gum infection which causes inflammation of the gums and damages soft tissue. Most people are not aware they have or have had this disease.

 

A recent study found that more than 90% of people with Alzheimer’s disease had evidence of the Periodontitis bacteria, P. gingivalis, in their brain. The GAIN study will be investigating a new medication that aims to slow the progression of Alzheimer’s disease by blocking the toxic proteins, called gingipains, released by these bacteria.

 

 

Individuals aged between 55-80 with a diagnosis of Alzheimer’s disease are eligible to participate. At St Pancras Clinical Research we have a team of industry experts specialising in cognition who are committed to the development of new medicine that aims to prevent and slow down the progression of Alzheimer’s disease.

 

Participating in the GAIN Study

 

St Pancras Clinical Research assists with travel arrangements and reasonable travel expenses and refreshments will be reimbursed.

 

Taking part in a clinical research study is a big decision for both the person who is participating and also their family and friends. We work together with you and your family to ensure you are aware of the commitments and all aspects of the study before committing. if someone gets in touch with us about taking part in research, one of our experienced team will have a confidential phone chat to discuss the study and that person’s suitability based on medical history, diagnosis and current medications. If suitable and the person would like to go ahead, we would then invite them in for a Patient Information Visit to meet the clinic team, discuss the study in more detail and get the opportunity to ask any questions and raise any concerns they might have.

 

Benefits of research:

 

  • You will have access to potential new medications before they are made available to the general population
  • You will have regular support including assessments and check-ups by leading healthcare professionals
  • You will be contributing to the development and understanding of new medications that currently do not have effective treatment options
  • We liaise directly with your GP about any medical concerns for the duration of the study

 

Are you eligible?

 

To take part you need to:

 

  • be between the ages of 55-80 years old

 

  • have a diagnosis of mild to moderate Alzheimer’s disease

 

  • have someone who is willing and able to be your study partner

If you think you might be eligible, you can complete our online form by clicking the button below, and a member of our Patient Engagement team will be in touch.